A clinical trial evaluating the efficacy of Cannabidiol (CBD) in treating post-operation pain showed some promising results, and TR Processing LLC is to thank.
The company describes itself as a “botanical-derivative manufacturer on a mission to transform health and well-being by proving and commercializing pharmaceutical ingredients,” and recently revealed that they supplied the CBD for clinical testing at NYU Langone Health and Baptist Health/Jacksonville Orthopaedic Institute. The trial was an attempt to evaluate the safety of CBD as well as to analyze its overall impact on post-op pain management. Patient satisfaction and subsequent opioid consumption were also taken into account during the testing.
A total of 99 participants were chosen randomly, all were between the ages of 18-75, and were either given the CBD or a placebo. The medicine was administered buccally, or between the gums and cheek to be absorbed into the blood. The following day, those who were given the CBD “experienced on average 23 percent less pain” as opposed to those who had received the placebo. In addition, they also experienced “22 to 25 percent greater satisfaction with pain control” in the first two days following their surgeries.
Another positive result was that no “major side-effects were reported” during the trial.
Opioids are notoriously addictive, yet are often used to manage pain in patients who are post-op. Unfortunately, some quickly become addicted to the medicine and rely on it long after the healing process is finished. According to the Centers for Disease Control (CDC) an estimated 100,306 people died from drug overdoses from April 2020 to April 2021. When it comes to opioids specifically, “[t]he new data documents that estimated overdose deaths from opioids increased to 75,673 in the 12-month period ending in April 2021, up from 56,064 the year before.”
It is for this reason that medical professionals are searching for effective alternatives to opioids for pain management in their patients.
Kevin Kaplan, M.D., FAAOS, orthopedic surgeon and Jacksonville Jaguars head team physician was the one to lead the Baptist Health/Jacksonville Orthopaedic Institute trial, and he had some positive things to say about TR Processing and its role in the event.
“We performed an exhaustive search looking for a manufacturer that could provide consistent and quality raw ingredients, while acknowledging the strict standard under which the FDA and pharmaceutical industry operate. We found that in TRP and thank them for their support,” he said.
Andrea G. Barthwell, M.D., former deputy director of Demand Reduction at The Office of National Drug Control Policy under President George W. Bush, was recently appointed to the TRP board of directors. She has worked with cannabinoids in the past, advising GW Pharmaceuticals regarding their Food and Drug Administration application for Sativex which is described as “a cannabinoid-based drug prescribed for spasticity related to multiple sclerosis.”
“I am excited by TRP’s focus on responsible development of cannabinoids and believe patients, physicians, and pharmaceutical companies are looking for safe and effective solutions for pain management and general health and well-being,” she said.
TRP chief strategy officer Chris Kanaley reiterated the company’s support for safer pain-management alternatives and reducing the use of, and hopefully addiction to, opioids.
“We are committed to supporting the study and responsible commercialization of isolated cannabinoids, including CBD. Tackling opioid abuse and addiction through the development of safer pain management alternatives is the first of many potential uses of our unique processing platform,” Kanaley said, “and we are enthusiastic about the future. Our work has tremendous potential to become precision medicine at its best.”
DONATE TO BIZPAC REVIEW
Please help us! If you are fed up with letting radical big tech execs, phony fact-checkers, tyrannical liberals and a lying mainstream media have unprecedented power over your news please consider making a donation to BPR to help us fight them. Now is the time. Truth has never been more critical!
- MTG gets some ‘savage’ payback after Dem across the hall loses reelection - November 10, 2022
- Musk sends first official email to Twitter staff; here’s what it said … - November 10, 2022
- Christina Pushaw laughs at traumatized local ‘legacy media’ calling Florida a ‘crimson hellscape’ - November 10, 2022
We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please click the ∨ icon below and to the right of that comment. Thank you for partnering with us to maintain fruitful conversation.